We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Kempharm Inc
2 own
6 watching
Current Price
$5.28
$-0.22
(-4%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
182.17M
52-Week High
7.38
52-Week Low
4
Average Volume
0.17M
Dividend Yield
--
P/E Ratio
--
Market Capitalization182.17M52-Week High7.3852-Week Low4Average Volume0.17MDividend Yield--P/E Ratio--What does the Kempharm Inc do?
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company s lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Read More
How much money does Kempharm Inc make?
News & Events about Kempharm Inc.
Globe Newswire
9days ago
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia (IH)CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company ...
Globe Newswire
16days ago
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare ...
Globe Newswire
1month ago
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severity of brain fog Interim efficacy and safety data expected as early as Q3 2023 CELEBRATION, Fla., Dec...
Globe Newswire
2 months ago
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and ...
Benzinga
2 months ago
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that KemPharm will report an earnings per share (EPS) of $-0.13.
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Kempharm Inc share price today?
Can Indians buy Kempharm Inc shares?
How can I buy Kempharm Inc shares from India?
Can Fractional shares of Kempharm Inc be purchased?
What are the documents required to start investing in Kempharm Inc stocks?
What is today’s traded volume of Kempharm Inc?
What is today’s market capitalisation of Kempharm Inc?
What is the 52-Week High and Low Range of Kempharm Inc?
What percentage is Kempharm Inc down from its 52-Week High?
What percentage is Kempharm Inc up from its 52-Week Low?
Current Price
$5.28
$-0.22
(-4%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.